AbbVie Inc. / Halozyme Therapeutics, Inc. (ENHANZE platform)
2015 · Licensing/Option · $1.2B · Terminated
Announcement Sentiment
57
Neutral / mixed
AbbVie and Halozyme entered a global collaboration applying Halozyme's ENHANZE platform to up to nine AbbVie targets. Halozyme received $23M upfront with up to $130M in milestones per target (~$1.17B aggregate across 9 targets). AbbVie terminated the collaboration November 2016.
Key facts
AnnouncedJun 03, 2015
ClosedJun 03, 2015
Deal value$1.2B
Deal typeLicensing/Option
Therapeutic areaMultiple (subcutaneous reformulation of biologics)
IndicationsMultiple (subcutaneous reformulation of biologics)
Key assetsENHANZE drug delivery technology applied to up to nine AbbVie targets
MechanismRecombinant human hyaluronidase enzyme (rHuPH20) enabling subcutaneous biologics